Efter aflæggelse af Q2 regnskabet afholdte BNs ledelse med analytikerne, deres investorpræsentation som kan ses via dette link. Her har man mulighed for at høre Q&A med analytikerne efter ledelsens indledende præsentation.
Bavarian Nordic indleder præsentationen sådan:
Highlights Q2 2020:
Revenue was DKK 1,065m
• Primarily driven by sale of new products and smallpox vaccine
•Other operating income of DKK 628m
• Sale of Priority Review Voucher in Q1
•EBITDA was DKK 839m
• Heavily frontloaded earnings due to PRV income with no costs associated
•Full year guidance maintained, cash upgraded
• Despite negative COVID-19 impact on new product segments, revenue and EBITDA
guidance are maintained due to strong outlook in other business areas
• Year-end cash position upgraded with DKK 150 million
